Patient with adequate organ functions
Adequate organ functions
Patient with adequate bone marrow reserve, hepatic and renal functions
Adequate organ and bone marrow functions evaluated during the  days prior to enrollment as follows:
Bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within  days prior to starting study Treatment
Adequate bone marrow and renal functions
Acceptable liver and renal functions defined as:
Adequate hepatic and renal functions as defined by:
Adequate hepatic and renal functions as defined by:
Adequate organ functions
Poor vital organ functions defined as:
Adequate bone marrow function, renal and liver functions
Adequate other organ functions
Have adequate values, bone marrow, renal and liver functions at screening as defined below:
Adequate bone marrow, liver and renal functions (tests must be performed within  days prior to enrollment).
Subjects who have adequate organ functions
Adequate organ system functions as defined by the laboratory assessments.
Adequate renal functions within  hours prior to induction chemotherapy
Adequate renal functions
Adequate hematopoietic, renal, and hepatic functions defined as:
Adequate haematological, hepatic and renal functions defined by the protocol
Subjects who have adequate hematological, renal, hepatic and respiratory functions defined.
Adequate organ and bone marrow functions
Patients must have adequate bone marrow, renal, hepatic, and neurologic functions
Adequate renal, hepatic, and hematologic functions per protocol-defined laboratory parameters within ?  days before treatment initiation.
Have adequate organ functions.
Adequate hematological, hepatic and renal functions.
Adequate hematologic, hepatic, renal, and coagulation functions
Patient must have completed radiation therapy with adequate recovery of bone marrow and organ functions, before starting neratinib
Participant has adequate organ functions, evidenced by the following:
Adequate bone marrow function, renal and liver functions
Adequate bone marrow, liver, and renal functions.
Adequate organ functions
Have clinically adequate hepatic and renal functions as defined by:
Adequate haematological, renal (creatinine < xULN), cardiac and liver functions
Adequate Bone Marrow, Renal and liver Functions.
Adequate liver and renal functions as assessed by the following laboratory requirements to be conducted within  days prior to starting study treatment:
Eligible study subjects must exhibit acceptable liver, bone marrow, renal and cardiac functions as assessed by laboratory tests, ECG and ECHO or MUGA scan.
Adequate organ and bone marrow functions
Adequate bone marrow, liver, and renal functions
Adequate bone marrow, liver, and renal functions, defined as:
Adequate liver and renal functions as assessed by the following laboratory requirements to be conducted within  days before the first dose of study drug:
Adequate organ and bone marrow functions.
Adequate bone marrow, liver, and renal functions as assessed by laboratory analysis to be conducted within  days prior to the first dose of study drug
Patient has adequate organ and bone marrow functions:
Bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within  days prior to starting study treatment
Adequate baseline functions:
Inadequate organ functions, positive pregnancy test.
Adequate liver and renal functions
Adequate hematologic, renal, and liver functions
Adequate Hepatic functions
Adequate bone marrow, liver, and renal functions
Patients must have adequate organ functions at the time of registration:
Adequate cardiac, renal, and hepatic functions.
Adequate hematological, liver, and renal functions
Adequate organ functions (hematological, hepatic, renal function)
Criteria , Adequate organ function within  wks prior to enrollment. This includes hematology, renal, hepatic and blood-clotting functions as defined by protocol.
Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements to be conducted within  days prior to the first dose of study drug:
Patient has adequate hematologic, hepatic, and renal functions
